Canalys' recent global wearable band market analysis forecasts a 2% rise in 2023, totaling to 186 million units. This growth is primarily driven by a significant 22% surge in basic watch shipments in emerging markets, notably India.

Quorum Cyber - with offices in Edinburgh, UK, and Tampa, Florida – has acquired Difenda, a Canadian-based, full-stack Microsoft Security Managed Services company. The announcement underscores Quorum Cyber's global momentum and strengthens its position as a leader of Microsoft Security services. 

By Arun Rasika Karunakaran, Retail Product Manager & Consultant,Tata Consultancy Services.

Over the last decade, the number of online sales has skyrocketed. The most recent statistics show that 19.4% of normal retail sales around the world were made online. That has led to some retailers thinking that it might be time to shift most of their focus to e-retail and their online storefronts.

Riverside Greetings, the supplier of greeting card solutions, has developed RFID (Radio Frequency Identification) and AI (Artificial Intelligence) technology which is claimed to dramatically accelerate category growth in the convenience and forecourt sector.

Following a record year in 2022, real-time data capture, printing, mobility and voice-directed solutions specialist, Dakota Integrated Solutions, has again exceeded projected revenue and growth targets during 2023.

RAIN Alliance, the non-profit industry organisation supporting the development and adoption of Ultra High Frequency (UHF) Radio Frequency Identification (RFID), has published its bi-annual research report ‘Global Markets & Applications for RAIN RFID Solutions’, produced by VDC Research.

In an effort to foster economic growth throughout Southern California's diverse communities, Cedars-Sinai has taken a lead role in creating a first-of-its-kind centralized resource directory designed to help diverse-owned vendors secure business opportunities with Southern California hospitals.

In an effort to foster economic growth throughout Southern California's diverse communities, Cedars-Sinai has taken a lead role in creating a first-of-its-kind centralized resource directory designed to help diverse-owned vendors secure business opportunities with Southern California hospitals.

[Economy] :
Global investment banks have slashed their growth outlook for South Korea for this year. According to the Korea Center for International Finance on Friday, the growth forecast by eight foreign investment banks averaged two-point-three percent at the end of October, representing a zero-point-two percentage ...

[more...]

[Economy] :
A state-run institute has revised down this year’s growth outlook by zero-point-three percentage point to two-point-two percent. In August, the Korea Development Institute(KDI) said it expected the economy to expand two-point-five percent in 2024. The institute said the economic recovery has weakened as ...

[more...]

[Economy] :
The nation added 83-thousand jobs in October, with job growth falling below 100-thousand for the first time in four months.  According to Statistics Korea on Wednesday, the number of employed people stood at 28-point-eight million last month, up 83-thousand from the same month last year. Job growth fell ...

[more...]

Low-concentration poly(ethylene oxide) exhibit the polymorph-dependent effects on both the surface and bulk crystal growth of carbamazepine polymorphs. These polymorph-dependent effects of PEO were mainly attributed to the polymer enrichment at the interface and different crystal surface-polymer interactions.

The crystal structure of the intracellular domain of transforming growth factor β type I receptor (TβR1) in complex with the competitive inhibitor SB505124 is presented. The study provides insights into the structure and function of TβR1 in complex with SB505124, and as such offers molecular-level understanding of the inhibition of this critical signalling pathway. The potential of SB505124 as an avenue for therapy in cancer treatment is discussed on basis of the results.

The expansive scientific software ecosystem, characterized by millions of titles across various platforms and formats, poses significant challenges in maintaining reproducibility and provenance in scientific research. The diversity of independently developed applications, evolving versions and heterogeneous components highlights the need for rigorous methodologies to navigate these complexities. In response to these challenges, the SBGrid team builds, installs and configures over 530 specialized software applications for use in the on-premises and cloud-based computing environments of SBGrid Consortium members. To address the intricacies of supporting this diverse application collection, the team has developed the Capsule Software Execution Environment, generally referred to as Capsules. Capsules rely on a collection of programmatically generated bash scripts that work together to isolate the runtime environment of one application from all other applications, thereby providing a transparent cross-platform solution without requiring specialized tools or elevated account privileges for researchers. Capsules facilitate modular, secure software distribution while maintaining a centralized, conflict-free environment. The SBGrid platform, which combines Capsules with the SBGrid collection of structural biology applications, aligns with FAIR goals by enhancing the findability, accessibility, interoperability and reusability of scientific software, ensuring seamless functionality across diverse computing environments. Its adaptability enables application beyond structural biology into other scientific fields.

The hardware for data archiving has expanded capacities for digital storage enormously in the past decade or more. The IUCr evaluated the costs and benefits of this within an official working group which advised that raw data archiving would allow ground truth reproducibility in published studies. Consultations of the IUCr's Commissions ensued via a newly constituted standing advisory committee, the Committee on Data. At all stages, the IUCr financed workshops to facilitate community discussions and possible methods of raw data archiving implementation. The recent launch of the IUCrData journal's Raw Data Letters is a milestone in the implementation of raw data archiving beyond the currently published studies: it includes diffraction patterns that have not been fully interpreted, if at all. The IUCr 75th Congress in Melbourne included a workshop on raw data reuse, discussing the successes and ongoing challenges of raw data reuse. This article charts the efforts of the IUCr to facilitate discussions and plans relating to raw data archiving and reuse within the various communities of crystallography, diffraction and scattering.

The two most abundant CaCO3 polymorphs, calcite and aragonite, are universally recognized for the richness of their morphology to which different twins make relevant contributions. The epitaxial transformation calcite ↔ aragonite has long been debated. While the twinning has been thoroughly treated, the homo-epitaxy occurring within each of these minerals has, inexplicably, been overlooked to date, both experimentally and theoretically. Twinning can be deceptive to the point where it can be mistaken for homo-epitaxy, thus making the proposed growth mechanism in the crystal aggregate wrong. Within the present work, the first aim is a theoretical investigation of the homo-epitaxies among the three {10.4}-cleavage, {01.2}-steep and {01.8}-flat rhombohedra of calcite. Accordingly, the specific adhesion energies were calculated between facing crystal forms, unequivocally showing that the {01.2}/{01.8} homo-epitaxy competes with the generation of both {01.2} and {01.8} contact twins. Secondly, the calculation of the specific adhesion energy was extended to consider homo-epitaxy for the {10.4} rhombohedron. The two-dimensional geometric lattice coincidence has been tried for the {00.1} pinacoidal form as well.

Here, a morphologically based approach is used for the in situ characterization of 3D growth rates of facetted crystals from the solution phase. Crystal images of single crystals of the β-form of l-glutamic acid are captured in situ during their growth at a relative supersaturation of 1.05 using transmission optical microscopy. The crystal growth rates estimated for both the {101} capping and {021} prismatic faces through image processing are consistent with those determined using reflection light mode [Jiang, Ma, Hazlehurst, Ilett, Jackson, Hogg & Roberts (2024). Cryst. Growth Des. 24, 3277–3288]. The growth rate in the {010} face is, for the first time, estimated from the shadow widths of the {021} prismatic faces and found to be typically about half that of the {021} prismatic faces. Analysis of the 3D shape during growth reveals that the initial needle-like crystal morphology develops during the growth process to become more tabular, associated with the Zingg factor evolving from 2.9 to 1.7 (>1). The change in relative solution supersaturation during the growth process is estimated from calculations of the crystal volume, offering an alternative approach to determine this dynamically from visual observations.

Paymentology has entered into a referral partnership with...

Klarna has secured a deal to offload BNPL loans that it...

Source: Streetwise Reports 11/08/2024

Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. The report has demonstrated the company's continued revenue growth and the strengthening of its innovative pipeline. For Q3 2024, Vertex's product revenue reached US$2.77 billion, a 12% increase from the previous year. This was primarily driven by strong demand for its TRIKAFTA®/KAFTRIO® therapies. Based on this momentum, Vertex raised its full-year product revenue guidance to a range of US$10.8 billion to US$10.9 billion, citing a solid trajectory in its cystic fibrosis (CF) portfolio and expected future launches.

In Q3, the company made notable advancements in its pipeline. Three programs have begun moving into Phase 3 clinical development: suzetrigine in diabetic peripheral neuropathy (DPN), povetacicept in IgA nephropathy (IgAN), and VX-880 in type 1 diabetes (T1D). Vertex is also preparing for the launch of two potential treatments in early 2025, with PDUFA dates set for January 2 for the vanzacaftor triple therapy for CF and January 30 for suzetrigine, the latter being a pain medication in a new therapeutic class aimed at reducing reliance on opioids.

GAAP and Non-GAAP net income both reached US$1.0 billion, largely driven by increased product revenue, which offset rising R&D and SG&A expense. This was s due to investments in global commercialization and late-stage clinical development. For Q3, Vertex's combined R&D and SG&A expenses were US$1.2 billion and US$1.1 billion, respectively, an increase from last year attributed to new global program advancements and upcoming launch support.

Vertex's cash position remained strong, with US$11.2 billion in cash, cash equivalents, and marketable securities as of September 30. The decline from US$13.7 billion at the end of 2023 primarily reflects the acquisition of Alpine Immune Sciences and share repurchases under the company's buyback program.

A Look At Biotechnology and Pharma

The U.S. Pharmaceuticals Report for 2024 by Nova One Advisor detailed the size and growth trajectory of the U.S. pharmaceutical market. Valued at US$602.19 billion in 2023, the sector is projected to exceed US$1 trillion by 2033. The report pointed to a "high healthcare expenditure provided by government bodies" as a primary growth driver, further bolstered by the aging population's demand for advanced treatments.

In an October 24 article, The Investing News Network reported on a dynamic landscape within the biotechnology sector. The report highlighted advancements in AI-powered drug discovery. Despite a cautious investment climate, interest remained strong in AI's potential to reshape healthcare, with venture capital investment reaching US$6.59 billion. At the HealthTech Ignite conference, Susie Roberts from Relay Therapeutics expressed confidence, noting, "We will definitely see AI design drugs in the next 10 years."

On November 4, Yahoo! Finance shared insights from MIT professors Andrew Lo and Dennis Whyte. They emphasized that biotechnology's rapid advancement over the past five decades offers valuable lessons for future innovation. In their research paper, Lo and Whyte proposed initiatives to accelerate biotechnology's growth, underscoring the importance of "reducing risk and uncertainty" to foster a robust investment ecosystem that supports groundbreaking discoveries.

Catalysts Driving Vertex Pharma

According to Vertex's November 2024 investor presentation, the company sees multiple growth catalysts over the next few years. Vertex aims to meet its goal of achieving "five launches in five years," focusing on expanding the treatable patient base in CF with vanzacaftor triple, addressing critical needs in sickle cell disease (SCD) and beta thalassemia (TDT) with CASGEVY, and launching suzetrigine for acute pain management.

Additionally, Vertex expects its expansive R&D pipeline to support long-term growth. This includes pivotal clinical trials for VX-880 in T1D, povetacicept in IgAN, and NaV1.8 pain inhibitors like suzetrigine, indicating a commitment to treating a range of chronic and life-threatening conditions with limited therapeutic options.

By driving advancements in CF therapies, diversifying its portfolio with novel pain treatments, and pursuing accelerated approvals for renal and blood-related disorders, Vertex is strategically positioning itself to sustain growth and achieve several near-term milestones.

What Are Experts Saying About Vertex?

In a November 5, 2024, H.C. Wainwright & Co. update, the analysts highlighted promising data from Vertex's recent Phase 2 trial for suzetrigine, which showed encouraging reductions in pain intensity. [OWNERSHIP_CHART-4085]

The analysts noted that suzetrigine's peripheral nervous system-specific mechanism could potentially address "a significant, unmet medical need worldwide" in non-opioid pain management. They set a price target of US$600.00, projecting Vertex's continued growth from its strong cystic fibrosis franchise and pipeline expansion.

From the November 7 Kingswood Capital Partners report, analysts noted Vertex Pharmaceuticals' "sustained execution" in advancing product development programs and achieving robust operating margins, enabling "continued, significant investments" in both its pipeline and commercial capabilities. The firm maintained a "Buy" rating with a 12-month target price of US$550.00, attributing this outlook to Vertex's deep cash resources and historical successes in clinical trials.

Ownership and Share Structure

According to Refinitiv, 95.44% of Vertex Pharmaceuticals is held by Institutions. The top among them are Capital World Investors at 10.37%, The Vanguard Group at 8.88%, BlackRock Institutional Trust with 5.49%, State Street Global Advisors (US) with 4.55%, and Fidelity Management and Research with 4.11%. Strategic Investors hold .12%. The rest is retail.

The company's market cap is US$129,395.59 million with 257.07 million free float shares. The 52 week range is US$341.90–$510.64.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: VRTX:NASDAQ, )

On-Demand Webcast>  Watch Now!SPONSORED BY: SageWatch this FREE on-demand webcast to hear from industry leaders as they walk you through 3 strategies for using ERP to drive productivity and ef...

Vox Royalty Corp. (VOXR:TSX.V) reported its Q3 2024 financial results. Read more on how strong cash flow growth, record production, and key project milestones are driving these results.

Silver Crown Royalties Inc. (SCRI:CBOE; SLCRF:OTCQX; QS0:FSE) announced record quarterly revenues in its financial results for the third quarter ending on September 30, 2024. Read more about the impressive growth in silver deliveries and how the company is strategically positioned for continued expansion.

Joint statements from the national science academies of the G7 nations were delivered today to the Italian government in advance of the G7 Summit to be held in Taormina, Italy, at the end of May.

Summer is a chance for children and youth to continue developing, but for those living in disadvantaged communities, summertime experiences can lead to worse health, social, emotional, academic, and safety outcomes, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Talking about Uttar Pradesh, Wani said the development of cities like Lucknow, Noida, and Ghaziabad as key financial hubs underscore the state's commitment to harnessing the growth potential.

GCC leaders discuss how by breaking silos, fostering collaboration, and focusing on execution and innovation, GCCs will be instrumental in India’s journey toward becoming a global economic powerhouse.

India-centric IT firms saw signs of recovery in the first half of the fiscal year, driven by growing tech spends in North America's BFSI sector, increased hiring, and improved revenue guidance. Experts foresee further tech spending bolstered by Donald Trump's US election win, which may lead to lower business taxes and favor skilled immigration, setting the stage for Indian IT firms to expand and innovate.

The 24% quarterly growth follows a slower-than-expected 16% growth in the January to March quarter, as reported by ET in May. While certain segments like pharma and eye wear have grown at a faster clip, senior ecommerce industry executives said there is an emerging trend of slowdown in online sales of low-priced items across categories like fashion, appliances, etc.

The survey indicates that 57% of CEOs believe stakeholder expectations on ESG are evolving faster than they can adjust their strategies, with more than half concerned that inadequate climate adaptation could negatively impact growth in the short to medium term.

Despite the noise around AI in the market right now, it is going to take time for companies to develop and adapt to the technology, Kalra said. On the business front, the company expects to fair well despite the challenging global environment and continue on its plan to expand in Europe and Asia Pacific while continuing the North America focus.

Commerce Secretary Sunil Barthwal stressed how India's growth rate is nearly double that of other emerging market economies. He was speaking at an event in Singapore organized by the commerce ministry to showcase various investment opportunities in India.

In his webinar “Edible Evolution in Cannabis: In Review and What’s to Come,” BDSA’s Rick Maturo breaks down the performance of cannabis food and beverage categories.

Downey's Potato Chips has upgraded its machinery with new Vanmark peeling machines.

American takeout standbys like pizza and Chinese food should watch their backs, because Mexican cuisine is close behind, says the “Global Palates 2015” report from the National Restaurant Association.

Several factors are prompting the company to reduce its sales and earnings expectations for the fiscal year ending in May 2015.

Tortillas have become a versatile carrier for many meals. While typically associated with Mexican foods, tortillas can be used across a broad range of foods and cuisines. 

Joel Clark, founder of Baker Mills and the Kodiak Cakes brand, got his start in the food business when he was just 8 years old, pulling a wagon around his Salt Lake City neighborhood selling whole-grain pancake mix in paper bags door-to-door. His mom ground the wheat. It was his grandfather's recipe.

After nearly eight years as editor, on August 1, I succeeded my longtime colleague, mentor, and friend, Chris Luke, as publisher of Snack Food & Wholesale Bakery. 

Nuts and seeds are growing in popularity due to an increase in healthy snacking and consumer interest in plant-based products. According to Innova Market Insights, 7 in 10 U.S. consumers sought healthier snacking options in 2018.

Since the beginning of 2020, when the COVID-19 pandemic began its destructive spread across the earth, the baking industry has seen highs and lows unlike any other time in history. This unprecedented challenge has reshaped our world, and much of the industry is emerging stronger than ever.

Crackers maintain far-reaching appeal. But while the category benefits from increased consumer interest in snacking, crackers have experienced intensified competition from other foods within salty snacks and beyond.

When the COVID-19 pandemic hit the U.S., shoppers began to frantically stock up on select food products. Due to its convenience and comfort-food appeal, frozen pizza was a top choice, and retailers soon found themselves with dwindling supplies as American society braced for the worst.

MECATHERM has launched the Authentik Baguette, a solution that allows manufacturers to meet the new expectations of consumers looking for more authentic products, with a product positioned midway between the classic baguette and the artisan-style baguette. 

Category analysis for fresh bread products like breads, buns, rolls, bagels, and English muffins, including sales data and product development strategies.

State of the Industry analysis of the fresh bread category, including sandwich and loaf bread products, bagels, and English muffins.

State of the Industry analysis of the fresh bread category, including coverage of loaf and sandwich breads, artisan breads, bagels, and English muffins.

The future for young women in this industry is now as bright as anyone wants it to be. If a young woman wants to work her way all the way up to the C-suite, the opportunities are there, and that is so exciting to see.

The skilled trades industry is evolving as more Gen Z workers choose trades over college. Efforts to obtain certifications through learning modules and hands-on training are becoming integrated into daily work routines, helping tradespeople build long-lasting careers and enabling businesses to succeed.